Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10,024 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H. Schroth W, et al. Among authors: schmidt m. JAMA. 2009 Oct 7;302(13):1429-36. doi: 10.1001/jama.2009.1420. JAMA. 2009. PMID: 19809024 Free PMC article.
Prognostic impact of haemoglobin levels in breast cancer.
Boehm DU, Lebrecht A, Schmidt M, Siggelkow W, Lindner C, Litz A, Ulbrich E, Koelbl H. Boehm DU, et al. Among authors: schmidt m. Anticancer Res. 2007 Mar-Apr;27(2):1223-6. Anticancer Res. 2007. PMID: 17465267 Free article.
ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
Brase JC, Schmidt M, Fischbach T, Sültmann H, Bojar H, Koelbl H, Hellwig B, Rahnenführer J, Hengstler JG, Gehrmann MC. Brase JC, et al. Among authors: schmidt m. Clin Cancer Res. 2010 Apr 15;16(8):2391-401. doi: 10.1158/1078-0432.CCR-09-2471. Epub 2010 Apr 6. Clin Cancer Res. 2010. PMID: 20371687
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M; EP Investigators. Filipits M, et al. Among authors: schmidt m. Clin Cancer Res. 2011 Sep 15;17(18):6012-20. doi: 10.1158/1078-0432.CCR-11-0926. Epub 2011 Aug 1. Clin Cancer Res. 2011. PMID: 21807638
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.
Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart M, Harbeck N. Schuler M, et al. Among authors: schmidt m. Breast Cancer Res Treat. 2012 Aug;134(3):1149-59. doi: 10.1007/s10549-012-2126-1. Epub 2012 Jul 5. Breast Cancer Res Treat. 2012. PMID: 22763464 Free PMC article. Clinical Trial.
10,024 results
You have reached the last available page of results. Please see the User Guide for more information.